Therapeutic Catalyst supports academic researchers in early drug discovery, funding target identification, validation and early antibody or small molecule development to advance treatments for adult cancers.
Childhood Cancer Therapeutic Catalyst supports academic researchers in collaborative early drug discovery to advance novel therapeutics for children and young people with cancer.
Scientific or educational activities grants support researchers, drug development professionals, academics, students, and fellows through non-promotional education in AstraZeneca’s R & D Discovery area.
Cancer Research UK's CDD supports the development of novel cancer agents from preclinical stages to early clinical trials with expert resources, not monetary funding.
UKRI Translation: MRC Impact Acceleration Awards support academic researchers to test a high-risk development step for medical products or interventions, generating evidence to guide progress towards patient benefit.